In pharma, you can take a larger slice of the healthcare pie than your peers, but…
Tag: abbv
$19 Billion in a Week: AbbVie Makes Two Big Bets
Early last week, AbbVie was on every healthcare investment banker’s list. But with two quick deal…
Even Mark Cuban Can’t Fix This Broken Drug System
Coherus Biosciences’ partnership to offer the deeply discounted biosimilar Humira could only go further in driving…
The End of AbbVie’s $200 Billion Monopoly Won’t Sink the Stock
The drugmaker is heavily discounting its immune-disease drug Humira to protect market share this year.
WSJ News Exclusive | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
pharmaceutical company ABV Inc. is looking for its next hit. Now its blockbuster immune-disease therapy Humira…
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
Pharmaceutical companies may try to cap the price hike in future.
World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen
Markets Heard on the Street As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be…
World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen
Markets Heard on the Street As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be…
Lack of Optimism for Alzheimer’s Trials Means There’s Little to Lose
Companies seeking a treatment for Alzheimer’s disease have spent an astonishing amount of money in recent…